Brittani Agostini
Director of Clinical Operations at Krystal Biotech
Pittsburgh, Pennsylvania
Summary
Experienced clinical operations leader who has progressed through multiple roles at Krystal Biotech, now serving as Director of Clinical Operations. theorg+1
Hands-on clinical research nurse background with experience coordinating multidisciplinary clinical studies and ensuring adherence to Good Clinical Practice. theorg+1
Active contributor to peer-reviewed research and clinical trial publications, particularly in gene therapy and pulmonary/cystic fibrosis research. nih+2
Operational study contact for multiple ongoing Krystal Biotech-sponsored clinical trials, serving as a point of contact for sites and participants. clinicaltrials+2
Work
Education
Projects
Writing
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study
January 1, 2025Long-term safety and tolerability report for topical gene therapy B-VEC; Brittani Agostini listed among contributors.
Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa
January 1, 2024Case report describing ophthalmic administration of B-VEC (beremagene geperpavec) and associated clinical outcomes.
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
January 1, 2022Clinical trial report on the topical gene therapy beremagene geperpavec (B-VEC) for treating dystrophic epidermolysis bullosa.
Nasal epithelial cell culture fluorescence recovery after photobleaching for CFTR studies
January 1, 2022Research methods/article involving nasal epithelial cell culture techniques relevant to pulmonary research.
Inhaled Hypertonic Saline in Preschool Children With Cystic Fibrosis
January 1, 2019Clinical research article related to inhaled therapies in preschool children with cystic fibrosis; lists contributing authors including Brittani Agostini.